Effcet-site EC50 for etomidate by target-controlled infusion at loss of consciousness in breast cancer patients who accepted adjuvant chemotherapy

Abstract

Objective To determine the Effcet-site EC50 of etomidate to cause loss of consciousness in patients who accepted adjuvant chemotherapy. Methods According to the therapeutic before their operation,ninety breast cancer patients undergoing elective operations were allocated to 3 groups:non-adjuvant chemotherapy group (group Ⅰ ,n=30),Taxol group (group Ⅱ ,n=30),Adriamycine+Cyclophosphamide+5-Fu group (group Ⅲ ,n=30). TCI etomidate was given byup and down method for 10 min in each group. The ration of two close effect-site concentrations was 1.25. Record the state of consciousness of each patient.Results The EC50 in non-adjuvant chemotherapy group was 0.58 mg/L,the 95% confidence level was 0.53 mg/L～0.63 mg/L. The EC50 in Taxol group was 0.34 mg/L,the 95% confidence level was 0.32 mg/L～0.37 mg/L. The EC50 in non-adjuvant chemotherapy group was0.35μg/ml,the 95% confidence level was0.32 mg/L～0.39 mg/L.Conclusion The EC50 of etomidate to cause loss of consciousness in adjuvant chemotherapy group is low than control group. Key words: Etomidate,TCI; Unconsciousness; EC50